Biotechnology
GeneQuantum Healthcare's Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia
SUZHOU, China, May 15, 2022 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co., Ltd. (hereinafter referred to as "GeneQuantum"), a global innovative biotechnology company dedicated to the development of bioconjugate drugs, announced that two of the company's bioconjugate drug candidates have won...
2022-05-16 09:00
1072
Kintor Pharma Included in MSCI China Index
SUZHOU, China, May 15, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced today that the company's stock has been included in the MSCI China Index, e...
2022-05-15 18:28
2495
Dizal Announces New Data from the Phase I/II Study of Golidocitnib in Refractory or Relapsed Peripheral T Cell Lymphoma Selected for Oral Presentation at 2022 EHA Annual Meeting
SHANGHAI, May 13, 2022 /PRNewswire/ -- Dizal (SSE: 688192) will present the data from an ongoing phase I/II study of golidocitnib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T cell lymphoma (r/r PTCL) in oral session at the 27th European Hematology Association 2022 (EHA2022)...
2022-05-13 19:09
1698
Yiling Pharmaceutical: Lianhua Qingwen Approved in Nigeria
SHIJIAZHUANG, China, May 12, 2022 /PRNewswire/ -- Yiling Pharmaceutical disclosed Wednesday that it had received the medicine approval document for Lianhua Qingwen Capsules from the National Agency for Food and Drug Administration and Control (NAFDAC),Nigeria. The Product Category is Herbal and ...
2022-05-12 22:43
1605
Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress
SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , May 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of can...
2022-05-12 22:01
2283
BIORCHESTRA Participated in Formulation and Delivery
BOSTON, May 12, 2022 /PRNewswire/ -- BIORCHESTRA is a leading RNA therapeutics
company that develops novel RNA-based therapeutics and drug delivery systems
for neurodegenerative diseases.
2022-05-12 21:00
1033
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery
TAIPEI, May 12, 2022 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWO.6838
2022-05-12 20:00
825
A novel universal antiviral drug introduced in Korea
- Hyundai Bioscience launches CP-COV03 Phase 2 clinical trials - "To be an innovative medicine like penicillin that led to victory in the bacterial war" - Significant changes to the 'vaccine-dependent' virus response system SEOUL, South Korea, May 12, 2022 /PRNewswire/ -- The birth of a universa...
2022-05-12 18:19
1277
Zhimeng Biopharma Announces Dosing of First Subject of Its Novel Antiepileptic Drug Candidate CB03 in First-in-Human Phase I Clinical Trial
SHANGHAI, May 11, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), announced dosing of the first participant in the US Phase I study in healthy subjects of its innovative small-molecule KCNQ2/3 selective opener (CB03), developed for the treatment of refractory epilepsy. CB03 is...
2022-05-12 08:00
824
I Peace accelerates allogeneic iPSC-derived cell therapies with a high throughput method to identify a large number of donors with specific HLA haplotypes.
PALO ALTO, Calif., May 11, 2022 /PRNewswire/ -- I Peace, Inc. (CEO: Koji Tanabe ), aPalo Alto-based biotech start-up in the field of GMP cell manufacturing CDMO, announced that the company, in collaboration with Genequest Inc., aTokyo -based direct-to-consumer genetic testing service provider, e...
2022-05-12 00:00
1505
Asia's first molecular diagnostics company for women, INEX Innovate receives European CE-IVD Certification for its OvaCis(R) Rapid Test to detect cancer in ovarian cysts.
Revolutionary Ovarian Cancer Rapid Test Available Q4 2022 SINGAPORE, May 11, 2022 /PRNewswire/ -- Known as a pioneer in Asia's women's and fetal health industry,Singapore-based diagnostics developer, INEX Innovate has obtained a CE markfor its lead ovarian cancer product, the OvaCis® Rapid Test....
2022-05-11 22:00
1694
PharmAbcine to participate in Jefferies Global Healthcare Conference and BIO International Convention
DAEJEON, South Korea, May 11, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that Dr.Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to par...
2022-05-11 20:00
1353
Bridge Biotherapeutics to Announce Updated Data from its Phase 1 Study of BBT-176 in Advanced Non-Small Cell Lung Cancer in an Oral Presentation at IASLC 2022 World Conference on Lung Cancer
* Data analysis to explore demonstrated anti-tumor activity of BBT-176, a fourth generation EGFR TKI, in advanced non-small cell lung cancer SEONGNAM, South Korea , May 10 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on deve...
2022-05-10 21:00
766
Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers
SHANGHAI, May 10, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the phase I trial interim results of an investigator-initiated tri...
2022-05-10 20:50
784
AffaMed Therapeutics Holds DEXTENZA Launch and Advisory Board Meeting in Macau
SHANGHAI, May 9, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, held a DEXTENZA Launch and Advisory Board Meeting recently inMacau, f...
2022-05-10 09:00
804
iNtRON Biotechnology, Inc., Launches New Website
It aims to promote strategic collaborations in global while also highlights its many innovative advances and successful scientific ventures. BOSTON and SEOUL, South Korea, May 9, 2022 /PRNewswire/ -- The parent company of iNtODEWORLD, Inc., iNtRON Biotechnology, Inc., ("iNtRON" or "Company") is ...
2022-05-09 21:00
926
OBiO Technology to Present Data on OVersatile™ Platform for Process Development of Herpes Simplex Virus and Vaccinia Virus Products at the 25th ASGCT Annual Meeting
SHANGHAI, May 9, 2022 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. ('OBiO', SSE:688238.SH), a gene and cell therapy-focused biotechnology company, serving as a contract research organization for vectorology and functional genomics studies, and providing contract development and manuf...
2022-05-09 19:40
858
AskGene Limited Announces Completion of USD 20 Million Series A Financing Led by Qiming Venture Partners and TF Capital
CAMARILLO, Calif. and NANJING, China, May 8, 2022 /PRNewswire/ -- AskGene Limited ("AskGene"), a clinical-stage biopharmaceutical company focusing on discovery and development of innovative biological drugs, today announced the completion ofUSD 20 million in Series A financing. The financing was ...
2022-05-09 11:37
2490
JW Therapeutics to Present Latest Data of Carteyva® at 2022 ASCO Annual Meeting
SHANGHAI, May 8, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that it will present the latest clinical study data for Carteyva® via poster pre...
2022-05-09 09:00
1045
InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers
NANJING, China, May 8, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, today announced that it had completed $15 million in Series B+ Fin...
2022-05-09 08:04
1124
Week's Top Stories
Most Reposted
GLOBAL POLICY WILL REMOVE HEADACHES FROM INTERNATIONAL TRAVEL
[Picked up by 184 media titles]
2022-05-09 15:30
EquitiesFirst and 14 Peaks' Nimsdai Purja Begin Epic Journey to Top of the World
[Picked up by 158 media titles]
2022-05-12 12:00
Klook And KAYAK Announce Expanded Integration, Enabling Users To Access One of the Largest Inventories Of Things-To-Do
[Picked up by 151 media titles]
2022-05-10 12:27PureSoftware wins the "Excellence in Fintech Solutions" award for its flagship product Arttha
[Picked up by 147 media titles]
2022-05-13 08:00Agoda partners with Visa to offer interest-free credit card instalments across its property bookings
[Picked up by 145 media titles]
2022-05-11 20:33Most Read
CBAK Energy Obtains $29 Million Battery Order from European Customer
2022-05-13 21:15
7413
PINTEC ANNOUNCES ADS Ratio Change
2022-05-14 00:30
6962
